Resources

QA Panel Data form for oncho diagnostic test SD bioline

This publication captures the milestones and process used by PATH in its role as Market Manager for the introduction and scale of 7.1% chlorhexidine for umbilical cord care globally over the last ten years.

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s research studies assessing the feasibility and acceptability of self-injection in Uganda and Senegal. For more information, please visit www.path.org/dmpa-sc or email FPoptions@path.org.

This document was created to support ministry of health and nongovernmental partners as they develop strategies to introduce and scale up subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) to increase contraceptive options and access. Available in English and French, the publication provides practical guidance based on results, evidence, and learning from the pilot introductions of Sayana Press in four countries in Africa. For more information, visit www.path.org/dmpa-sc, sign up for our newsletter, or email FPoptions@path.org.

Answers to these simple questions will provide an effective 10-part plan to help you achieve important health policy changes and accountability.Hard copies available upon request.